Stay updated on Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial
Sign up to get notified when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.

Latest updates to the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAn updated site revision tag (v3.4.2) was added, and an existing government funding status notice (v3.4.1) was removed. The study’s content and data remain unchanged.SummaryDifference0.4%

- Check21 days agoChange DetectedA government funding notice and status update were added to the page footer. The site revision label was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a glossary toggle and updated metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0). Removed the older labels (Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4).SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing the previous Revision: v3.3.3.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section including Missouri (St. Louis, MO) for the study page and updated the revision to v3.3.3.SummaryDifference0.2%

- Check85 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; no changes to study details or page layout are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.